FIX BUTTONS AND LINKS BEFORE PUBLISHING
Join Our Virtual Event On May 19th!
Event will take place on Zoom and we will hear from Dr. Thomas Lechner from Ono Pharma US about a new research study that is underway for men and women with primary central nervous system lymphoma (PCNSL).
11am - 12:30pm
(PST)
Register By 5/10/23
Pre-Registration Required.
Event is free due to generous sponsorship!
Dr. Thomas Lechner joined Ono Pharma US in April 2022, assuming the role of Vice President, Medical Affairs, where he is responsible for establishing the company’s core medical strategy in the US.
Thomas brings over 20 years of Oncology Medical Affairs and Clinical Development experience in the US and Europe, and joined Ono Pharma US recently from Morphosys, where he was responsible for providing leadership and medical strategy for the US Medical Affairs organization. In his prior experience, Thomas held a variety of progressively responsible roles with both Boehringer-Ingleheim and Pfizer Oncology in the US and in Germany. Thomas has a Master of Science degree in Microbiology from the University of Innsbruck, Austria and a Doctoral degree (Dr. rer. nat) in Molecular Genetics/ Epigenetics from the University of Innsbruck, Austria. He conducted his postdoctoral research as a fellow at a Howard Hughes Medical Institute at Penn State University in the USA and presented his research at international congresses and has published in several peer-reviewed journals.
A message from EBCI's Founder & President…
“In the End Brain Cancer Initiative’s continued effort to bring direct disease education, awareness & outreach, as well as services & programs to patients/caregivers to ultimately increase patient access to specialists, advanced treatments, devices, diagnostics & clinical trials, we are proud to bring to the public and patient community, Dr. Thomas Lechner, VP Medical Affairs, Ono Pharma US, who is responsible for establishing Ono Pharma USA’s medical strategy in the U.S. to our 2023 “Know All Your Treatment Options” online meeting/event as our Keynote Speaker. Specifically, Thomas will also be presenting on the importance of collaboration with Advocacy organizations to increase patient access as well as “The PROSPECT Study”, for patients with primary CNS lymphoma (PCNSL), which only affects @ 1,500 people in the U.S.. annually”.
As a reminder, this year’s Hope Award Initiative and Campaign will run through May 5th, 2023, with the Award being presented at EBCI’s May 19th “Know All Your Treatment Options” Virtual Patient Education Meeting and Event.
May is Brain Cancer Awareness Month. Why not honor someone you love and respect and make a nomination? We would love to learn your story and be inspired.
EBCI helps guide brain tumor patients and their caregivers through their treatment journey including connecting and referring them to specialists in cancer centers offering the latest innovations in treating brain tumors. To learn more about the services that EBCI provides and to connect with our President & CEO please click through to our website and fill out a Research Collaboration Inquiry Form.
